Publication:
Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension

Simple item page
dc.contributor.coauthorAfsar, Baris
dc.contributor.departmentN/A
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorÖnal, Emine Meltem
dc.contributor.kuauthorSağ, Alan Alper
dc.contributor.kuauthorŞal, Oğuzhan
dc.contributor.kuauthorYerlikaya, Aslıhan
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileUndergraduate Student
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileUndergraduate Student
dc.contributor.kuprofileUndergraduate Student
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid110580
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokid341966
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T23:34:22Z
dc.date.issued2017
dc.description.abstractOrgan crosstalk pathways represent the next frontier for target-mining in molecular medicine for existing syndromes. Pulmonary hypertension and resistant essential hypertension are syndromes that have been proven elusive in etiology, and frequently refractory to first-line management. Underlying crosstalk mechanisms, not yet considered in these treatments, may hinder outcomes or unlock novel treatments. This review focuses systematically on erythropoietin, a synthesizable molecule, as a mediator of brain-kidney crosstalk. Insights gained from this review will be applied to cardiovascular diseases in a clinician-directed fashion.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.volume39
dc.identifier.doi10.1080/10641963.2016.1246565
dc.identifier.eissn1525-6006
dc.identifier.issn1064-1963
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85018312749
dc.identifier.urihttp://dx.doi.org/10.1080/10641963.2016.1246565
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12341
dc.identifier.wos400341300001
dc.keywords(MeSH) Crosstalk
dc.keywordsErythropoietin
dc.keywordsHypertension
dc.keywordsMolecular medicine
dc.keywordsRecombinant-human-erythropoietin
dc.keywordsNitric-oxide synthase
dc.keywordsRenin-angiotensin-aldosterone
dc.keywordsChronic-hemodialysis patients
dc.keywordsEndothelial progenitor cells
dc.keywordsAnalog darbepoetin-alpha
dc.keywordsSmooth-muscle-cells
dc.keywordsAcute lung injury
dc.keywordsBlood-pressure
dc.keywordsBarrier disruption
dc.languageEnglish
dc.publisherTaylor & Francis
dc.sourceClinical and Experimental Hypertension
dc.subjectPharmacology
dc.subjectPharmacy
dc.subjectPeripheral vascular disease
dc.titleErythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension
dc.typeReview
dspace.entity.typePublication
local.contributor.authorid0000-0002-1297-0675
local.contributor.authoridN/A
local.contributor.authorid0000-0002-3106-0458
local.contributor.authorid0000-0002-8771-8263
local.contributor.authorid0000-0001-6186-1646
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÖnal, Emine Meltem
local.contributor.kuauthorSağ, Alan Alper
local.contributor.kuauthorŞal, Oğuzhan
local.contributor.kuauthorYerlikaya, Aslıhan

Files

Collections

Publications without Fulltext